Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer

A series of 1,2,3-triazole analogues as novel fat mass and obesity-associated protein (FTO) inhibitors were synthesised in this study. Among all 1,2,3-triazoles, compound C6 exhibited the most robust inhibition of FTO with an IC50 value of 780 nM. It displayed the potent antiproliferative activity a...

Full description

Saved in:
Bibliographic Details
Main Authors: Bo Qin, Qian Bai, Dan Yan, Fanxiang Yin, Zhu Zhu, Chaoyuan Xia, Yang Yang, Yi Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2022.2098954
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849687139740024832
author Bo Qin
Qian Bai
Dan Yan
Fanxiang Yin
Zhu Zhu
Chaoyuan Xia
Yang Yang
Yi Zhao
author_facet Bo Qin
Qian Bai
Dan Yan
Fanxiang Yin
Zhu Zhu
Chaoyuan Xia
Yang Yang
Yi Zhao
author_sort Bo Qin
collection DOAJ
description A series of 1,2,3-triazole analogues as novel fat mass and obesity-associated protein (FTO) inhibitors were synthesised in this study. Among all 1,2,3-triazoles, compound C6 exhibited the most robust inhibition of FTO with an IC50 value of 780 nM. It displayed the potent antiproliferative activity against KYSE-150, KYSE-270, TE-1, KYSE-510, and EC109 cell lines with IC50 value of 2.17, 1.35, 0.95, 4.15, and 0.83 μM, respectively. In addition, C6 arrested the cell cycle at G2 phase against TE-1 and EC109 cells in a concentration-dependent manner. Analysis of cellular mechanisms demonstrated that C6 concentration-dependently regulated epithelial mesenchymal transition (EMT) pathway and PI3K/AKT pathway against TE-1 and EC109 cells. Molecular docking studies that C6 formed important hydrogen-bond interaction with Lys107, Asn110, Tyr108, and Leu109 of FTO. These findings suggested that C6 as a novel FTO inhibitor and orally antitumor agent deserves further investigation to treat esophageal cancer.
format Article
id doaj-art-e58db9ffe40344579e77658a6f58986e
institution DOAJ
issn 1475-6366
1475-6374
language English
publishDate 2022-12-01
publisher Taylor & Francis Group
record_format Article
series Journal of Enzyme Inhibition and Medicinal Chemistry
spelling doaj-art-e58db9ffe40344579e77658a6f58986e2025-08-20T03:22:26ZengTaylor & Francis GroupJournal of Enzyme Inhibition and Medicinal Chemistry1475-63661475-63742022-12-013711995200310.1080/14756366.2022.2098954Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancerBo Qin0Qian Bai1Dan Yan2Fanxiang Yin3Zhu Zhu4Chaoyuan Xia5Yang Yang6Yi Zhao7Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR ChinaDepartment of Anesthesiology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR ChinaTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR ChinaTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR ChinaTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR ChinaTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR ChinaTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR ChinaTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR ChinaA series of 1,2,3-triazole analogues as novel fat mass and obesity-associated protein (FTO) inhibitors were synthesised in this study. Among all 1,2,3-triazoles, compound C6 exhibited the most robust inhibition of FTO with an IC50 value of 780 nM. It displayed the potent antiproliferative activity against KYSE-150, KYSE-270, TE-1, KYSE-510, and EC109 cell lines with IC50 value of 2.17, 1.35, 0.95, 4.15, and 0.83 μM, respectively. In addition, C6 arrested the cell cycle at G2 phase against TE-1 and EC109 cells in a concentration-dependent manner. Analysis of cellular mechanisms demonstrated that C6 concentration-dependently regulated epithelial mesenchymal transition (EMT) pathway and PI3K/AKT pathway against TE-1 and EC109 cells. Molecular docking studies that C6 formed important hydrogen-bond interaction with Lys107, Asn110, Tyr108, and Leu109 of FTO. These findings suggested that C6 as a novel FTO inhibitor and orally antitumor agent deserves further investigation to treat esophageal cancer.https://www.tandfonline.com/doi/10.1080/14756366.2022.2098954FTO1,2,3-triazoleesophageal cancercell cyclemolecular docking
spellingShingle Bo Qin
Qian Bai
Dan Yan
Fanxiang Yin
Zhu Zhu
Chaoyuan Xia
Yang Yang
Yi Zhao
Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer
Journal of Enzyme Inhibition and Medicinal Chemistry
FTO
1,2,3-triazole
esophageal cancer
cell cycle
molecular docking
title Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer
title_full Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer
title_fullStr Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer
title_full_unstemmed Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer
title_short Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer
title_sort discovery of novel mrna demethylase fto inhibitors against esophageal cancer
topic FTO
1,2,3-triazole
esophageal cancer
cell cycle
molecular docking
url https://www.tandfonline.com/doi/10.1080/14756366.2022.2098954
work_keys_str_mv AT boqin discoveryofnovelmrnademethylaseftoinhibitorsagainstesophagealcancer
AT qianbai discoveryofnovelmrnademethylaseftoinhibitorsagainstesophagealcancer
AT danyan discoveryofnovelmrnademethylaseftoinhibitorsagainstesophagealcancer
AT fanxiangyin discoveryofnovelmrnademethylaseftoinhibitorsagainstesophagealcancer
AT zhuzhu discoveryofnovelmrnademethylaseftoinhibitorsagainstesophagealcancer
AT chaoyuanxia discoveryofnovelmrnademethylaseftoinhibitorsagainstesophagealcancer
AT yangyang discoveryofnovelmrnademethylaseftoinhibitorsagainstesophagealcancer
AT yizhao discoveryofnovelmrnademethylaseftoinhibitorsagainstesophagealcancer